GlassScriptPhysician profile
Christian A Gallo
NPI 1093281412
$14,807.27
in general payments reported to CMS, 2019-2025
32 companies · $4,350 in 2025
The $4,350 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,790 · 2022: $2,289 · 2023: $2,558 · 2024: $3,820 · 2025: $4,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,366.90 |
| Education | $361.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,972.78 | 2021-2025 | |
| Abbvie INC. | $1,756.63 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,162.73 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,081.43 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $971.08 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $924.02 | 2021-2025 | Tremfya |
| Amgen INC. | $800.40 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $685.35 | 2022-2025 | Sotyktu |
| Incyte Corporation | $667.10 | 2021-2025 | Opzelura |
| Genzyme Corporation | $635.63 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $569.49 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $549.13 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $483.83 | 2021-2025 | Adbry |
| Galderma Laboratories, L.P. | $456.95 | 2022-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $406.88 | 2023-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $399.17 | 2021-2025 | |
| Ucb, INC. | $309.58 | 2022-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.35 | 2021-2025 | Jublia, Cabtreo, Duobrii |
| Botanix Sb INC | $181.87 | 2025 | Sofdra |
| Organon LLC | $133.70 | 2025 | Vtama, Hadlima |
| Verrica Pharmaceuticals INC. | $55.24 | 2024-2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $48.30 | 2021 | |
| Genentech USA, INC. | $43.23 | 2021 | |
| Blueprint Medicines Corporation | $43.03 | 2023 | |
| Lnhc, INC | $42.77 | 2025 | Zelsuvmi |
| Almirall LLC | $42.26 | 2023-2025 | Seysara |
| Mallinckrodt Hospital Products INC. | $35.33 | 2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.27 | 2022 | |
| Journey Medical Corporation | $25.00 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.10 | 2021 | |
| Biofrontera INC. | $18.31 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.